Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

985 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Haas NB, et al. Among authors: kane c. Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Lancet. 2016. PMID: 26969090 Free PMC article. Clinical Trial.
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS. Haas NB, et al. Clin Cancer Res. 2015 Sep 15;21(18):4048-54. doi: 10.1158/1078-0432.CCR-15-0215. Epub 2015 May 12. Clin Cancer Res. 2015. PMID: 25967143 Free PMC article. Clinical Trial.
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Lee Z, et al. J Urol. 2020 Apr;203(4):684-689. doi: 10.1097/JU.0000000000000588. Epub 2019 Oct 9. J Urol. 2020. PMID: 31596672 Free PMC article.
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.
Correa AF, Jegede OA, Haas NB, Flaherty KT, Pins MR, Adeniran A, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG. Correa AF, et al. Eur Urol. 2021 Jul;80(1):20-31. doi: 10.1016/j.eururo.2021.02.025. Epub 2021 Mar 9. Eur Urol. 2021. PMID: 33707112 Free PMC article.
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
Karam JA, Puligandla M, Flaherty KT, Uzzo RG, Matin SF, Pins MR, Wood CG, Kane C, Jewett MAS, Kim SE, Dutcher JP, DiPaola RS, Haas NB. Karam JA, et al. Among authors: kane c. BJU Int. 2022 Jun;129(6):718-722. doi: 10.1111/bju.15587. Epub 2021 Sep 23. BJU Int. 2022. PMID: 34480522 Free PMC article. Clinical Trial.
985 results